NEUROSCIENCE
NEUROLOGICAL DISORDERS
FROM disease TO TREATMENT \ NEUROSCIENCE NEUROLOGICAL DISORDERS
Neurological disorders are among the leading causes of disability and reduced quality of life worldwide. Emerging research highlights the central role of cerebral metabolic alterations — including mitochondrial dysfunction, oxidative stress, impaired neurotransmitter synthesis, and neuroinflammation — in the pathophysiology of many neurological diseases.
Conditions such as central and peripheral neuropathies often involve significant disruptions in brain energy metabolism and neurotrophic support. These metabolic imbalances not only contribute to disease progression but are also closely linked to symptoms like neuropathic pain, neuroendocrine dysfunctions, and insomnia — all of which further impair neurological health and cognitive function.
Conditions such as central and peripheral neuropathies often involve significant disruptions in brain energy metabolism and neurotrophic support. These metabolic imbalances not only contribute to disease progression but are also closely linked to symptoms like neuropathic pain, neuroendocrine dysfunctions, and insomnia — all of which further impair neurological health and cognitive function.
Fidia Farmaceutici has long recognized the importance of targeting cerebral metabolic balance as a strategic therapeutic approach. Its commitment to neuroscience is reflected in a portfolio of products designed to support neuronal function, enhance neuroprotection, and restore metabolic homeostasis. In particular, Fidia offers solutions that address:
- Neuroendocrine imbalances, such as hypothalamic-pituitary axis dysfunctions, often seen in aging and neurodegenerative conditions;
- Neuropathic pain, a debilitating consequence of altered nerve signaling and metabolic stress;
- Insomnia, both as a symptom and an aggravating factor in neurological decline.
Through clinical research, scientific education programs like Fidia Academy: Rising in Neuroscience, and partnerships with healthcare professionals, Fidia continues to invest in innovative therapies that address the metabolic underpinnings of neurological disease — bringing science closer to patients.
CEREBRAL METABOLIC ALTERATIONS
Asthenia and fatigue are frequent and debilitating symptoms observed in many neurological and systemic conditions.
While often underestimated, these symptoms are increasingly understood as clinical expressions of cerebral metabolic dysfunction, with a key role played by alterations in neuronal cell membrane structure and function.
The cell membrane is essential for maintaining ionic gradients, neurotransmission, and energy metabolism.
When membrane integrity is compromised due to oxidative stress, inflammation, or lipid imbalance — neuronal efficiency declines, leading to impaired signal transmission and mental and physical fatigue.
While often underestimated, these symptoms are increasingly understood as clinical expressions of cerebral metabolic dysfunction, with a key role played by alterations in neuronal cell membrane structure and function.
The cell membrane is essential for maintaining ionic gradients, neurotransmission, and energy metabolism.
When membrane integrity is compromised due to oxidative stress, inflammation, or lipid imbalance — neuronal efficiency declines, leading to impaired signal transmission and mental and physical fatigue.
In neurological patients, such as those affected by neurodegenerative diseases, chronic pain, or post-inflammatory syndromes, membrane dysfunction may exacerbate central fatigue, reduce neuroplasticity, and contribute to a persistent sense of exhaustion that is not resolved by rest.
Fidia Farmaceutici is actively engaged in addressing these challenges through research and development of neurotrophic and metabolic therapies that support cell membrane repair and neuronal vitality. By focusing on mitochondrial efficiency, membrane phospholipid balance, and oxidative protection, Fidia aims to restore cerebral energy metabolism and improve patients’ functional status.
NEUROLOGICAL DISORDERS
Neuropathies and neuropathic pain represent a significant burden in neurological practice.
Characterized by damage or dysfunction of the peripheral or central nervous system, these conditions can result in persistent pain, sensory disturbances, muscle weakness, and reduced quality of life.
Characterized by damage or dysfunction of the peripheral or central nervous system, these conditions can result in persistent pain, sensory disturbances, muscle weakness, and reduced quality of life.
Neuropathic pain is particularly challenging: it is often chronic, resistant to conventional analgesics, and deeply impacts patients both physically and psychologically. It may arise from diverse causes such as diabetes, chemotherapy, viral infections, or mechanical nerve injury but shares common pathological mechanisms, including neuronal hyperexcitability, inflammation, and metabolic and structural nerve alterations.
Peripheral neuropathies, whether inflammatory, metabolic, or degenerative in origin, frequently involve disruption of nerve cell membranes, oxidative stress, and impaired axonal transport — factors that hinder nerve conduction and regeneration.
Fidia Farmaceutici is committed to supporting patients and clinicians in the management of these complex conditions through neurotrophic, antioxidant, and neuroprotective treatments that address both symptoms and underlying pathophysiology. By promoting nerve metabolism, cell membrane stability, and functional recovery, Fidia’s therapeutic approach aims to go beyond symptom relief to support true neuroregeneration.
Discover more
about our solutions
